Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 05:00 save search
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
review cancer treatment advanced china
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
HCM | $16.44 0.49% 28K
|
Health Technology
|
| O: 0.21%
H: 1.49%
C: -0.06%
treatment advanced china
TL1A Inhibitors Could Usher in New Era for IBD Treatment
Published: 2024-02-26 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
treatment
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
Published: 2024-01-30 (Crawled : 05:00) - globenewswire.com
HCM | $16.44 0.49% 28K
|
Health Technology
|
| O: -0.85%
H: 0.62%
C: -1.17%
elunate approval cancer treatment
Water and Wastewater Treatment Equipment Market to grow by USD 108.07 billion by 2027; Segmentation by type (primary treatment, secondary treatment, and tertiary treatment), application (municipal and industrial), and geography (APAC, North America, Europe, Middle East and Africa, and South America) - Technavio
Published: 2024-01-12 (Crawled : 05:00) - prnewswire.com
XYL | $128.13 0.76% 650K
|
Producer Manufacturing
|
| O: 0.41%
H: 0.6%
C: -0.36%
IR | News | $87.7 -1.43% 1.3M
|
Producer Manufacturing
|
| O: 0.51%
H: 0.1%
C: -0.86%
water treatment application market africa
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients
Published: 2023-12-27 (Crawled : 05:00) - prnewswire.com
CALT | News | $17.65 3K
|
Health Technology
|
| O: -3.52%
H: 1.97%
C: 1.89%
nefecon nephropathy drug treatment application
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
Published: 2023-11-24 (Crawled : 05:00) - prnewswire.com
CALT | News | $17.65 3K
|
Health Technology
|
| O: 3.31%
H: 0.81%
C: 0.81%
nefecon nephropathy approval treatment china
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
Published: 2023-10-27 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
MNOV | $1.4 9.6K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: -1.54%
treatment phenylketonuria therapy
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
Published: 2023-10-23 (Crawled : 05:00) - globenewswire.com
ROIV | $10.305 -0.53% 1.7M
|
Manufacturing
|
| O: 3.83%
H: 0.0%
C: -14.31%
rvt-3101 disease antibody treatment acquire roche agreement
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Published: 2023-10-23 (Crawled : 05:00) - globenewswire.com
ROIV | $10.305 -0.53% 1.7M
|
Manufacturing
|
| O: 3.83%
H: 0.0%
C: -14.31%
rvt-3101 announcement disease antibody treatment acquire roche agreement
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
Published: 2023-10-23 (Crawled : 05:00) - globenewswire.com
IOBT | $1.47 45K
|
|
| O: -3.14%
H: 5.24%
C: -1.97%
io102 lung congress cancer cell treatment medical trial
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
Published: 2023-10-04 (Crawled : 05:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
disease treatment collaboration teva sanofi
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Published: 2023-09-25 (Crawled : 05:00) - globenewswire.com
BIIB | $192.68 1.13% 590K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -0.81%
leqembi disease japan approved alzheimer’s treatment
Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of market growth- Technavio
Published: 2023-09-18 (Crawled : 05:00) - prnewswire.com
BHC | $8.63 0.35% 1.5M
|
Health Technology
|
| O: -1.06%
H: 0.59%
C: -0.71%
ALC | $79.43 1.22% 760K
|
Health Technology
|
| O: -0.85%
H: 0.38%
C: -0.06%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
presbyopia treatment asia market
Onychomycosis Treatment Market size to grow by USD 1,776.53 million from 2022 to 2027; Growth driven by increasing prevalence of onychomycosis - Technavio
Published: 2023-08-15 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -2.02%
H: 0.0%
C: -1.05%
ALPMY | $9.47 520K
|
Manufacturing
|
| O: 0.78%
H: 0.39%
C: -2.39%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
GSK | $39.585 0.8% 1.1M
|
Health Technology
|
| O: -0.51%
H: 0.24%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
treatment growth market
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine
Published: 2023-06-08 (Crawled : 05:00) - globenewswire.com
BNR | $0.75 -6.25% 5.8K
|
Health Services
|
| O: -0.45%
H: 3.15%
C: 0.45%
breast cancer diagnostics results
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
Published: 2023-04-21 (Crawled : 05:00) - prnewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.53%
H: 0.37%
C: -0.11%
qulipta abbvie treatment meeting trial migraine results
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -2.69%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.3%
H: 1.86%
C: 0.82%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: 1.05%
H: 0.2%
C: -0.16%
treatment designation drug medical application granted review china
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
Published: 2022-07-19 (Crawled : 05:00) - biospace.com/
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment fda approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
Published: 2022-04-06 (Crawled : 05:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $52.07 -1.42% 800K
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment test diagnostic approval one therapy
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.